(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/077831 A1

(51) International Patent Classification:
C07K 16/46 (2006.01) *A61P 37/00* (2006.01)
A61K 39/395 (2006.01) *C12N 15/11* (2006.01)

(21) International Application Number:
PCT/CN2024/124154

(22) International Filing Date:
11 October 2024 (11.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202311318859.2 12 October 2023 (12.10.2023) CN

(71) Applicant: **INNOVENT BIOLOGICS (SUZHOU) CO., LTD.** [CN/CN]; 168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(72) Inventors: **XIONG, Yao**; 168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **LI, Li**; 168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **ZHOU, Shuaixiang**; 168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **ZHU, Mengzhu**; 168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **FU, Jie**; 168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: **BEIJING SUNHOPE INTELLECTUAL PROPERTY LTD.**; Suite 1106, Kunxun Plaza, Zhichun Road 9, Haidian District, Beijing 100191 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: ANTI-IL-4RA/TSLP ANTIBODIES AND USES THEREOF

Test of CCL-17 release from peripheral blood PBMCs induced by IL-4, IL-13, and TSLP



	Dupilumab	Tezepelumab+Dupilumab	H6-5G-hz11H7-2-scFv	C3-5G-hz11H7-2-scFv
IC50	3.071	0.5789	0.5720	0.2243

E2-5G-hz11H7-2-scFv	D5-5G-hz11H7-2-scFv	Tezepelumab
0.2455	0.2516	~ 12.32

FIG. 11C

(57) Abstract: Provided are anti-IL-4Rα antibodies or antigen-binding fragments thereof, anti-TSLP antibodies or antigen-binding fragments thereof, antigen-binding protein constructs (e. g., multi-specific or bispecific antibodies capable of specifically binding to IL-4Rα and TSLP). Provided are polynucleotides encoding the antibodies or antigen-binding protein constructs, and expression vectors and host cells comprising the same. Also provided are immunoconjugates, pharmaceutical compositions and medicaments, as well as uses thereof for treating immune disorders (e.g., type II or mixed allergic diseases).

[Continued on next page]

WO 2025/077831 A1

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*